Describes the reorganization of drugs in the GlaxoSmithKline (GSK) after the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization has about 2,000 scientists and researchers in the six centers of excellence in drug discovery (CEDD). Each CEDD focused on a small set of therapeutic areas and has the right to address the progression of pharmaceutical drugs in the early stages of development. CEDDs described the proposed structure and its relationship with the rest of the centralized R & D departments of the organization GSK. Address questions about the benefits of diversification in focus against the R & D, the role of decentralized vs. coordinated solutions, and the importance of consistency between structural and infrastructure (for example, performance incentives) aspects of the operating model. Using the empirical context of mergers in the pharmaceutical industry, the event allows students to build a broad idea of the interaction between the legal form and operations. "Hide
by Robert S. Huckman, Eli Peter Strick Source: Harvard Business School 21 pages. Publication Date: May 17, 2005. Prod. #: 605074-PDF-ENG
Related Case Solutions & Analyses:
Totals Carbon Capture and Storage Project at LACQ (B): Gaining Public Acceptance of New Technology
Amyris Biotechnologies: Commercializing Biofuel
Perlegen Sciences
New Business Investment Co.: October 1997
City Year Enterprise
Booz.Allen & Hamilton: Vision 2000
Regency Plaza
Return-On-Investment and the Operations Manager
Emotion in Negotiations: An Introduction
A Note on Funding Digital Innovation Startups
